JP2019523221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523221A5 JP2019523221A5 JP2018561225A JP2018561225A JP2019523221A5 JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5 JP 2018561225 A JP2018561225 A JP 2018561225A JP 2018561225 A JP2018561225 A JP 2018561225A JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- seq
- antibody according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022023569A JP7331179B2 (ja) | 2016-05-27 | 2022-02-18 | 抗ｃｄ４０抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342417P | 2016-05-27 | 2016-05-27 | |
| US62/342,417 | 2016-05-27 | ||
| PCT/US2017/034681 WO2017205742A1 (en) | 2016-05-27 | 2017-05-26 | Anti-cd40 antibodies and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023569A Division JP7331179B2 (ja) | 2016-05-27 | 2022-02-18 | 抗ｃｄ４０抗体とその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019523221A JP2019523221A (ja) | 2019-08-22 |
| JP2019523221A5 true JP2019523221A5 (cg-RX-API-DMAC7.html) | 2020-07-02 |
Family
ID=59014833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561225A Withdrawn JP2019523221A (ja) | 2016-05-27 | 2017-05-26 | 抗ｃｄ４０抗体とその使用 |
| JP2022023569A Active JP7331179B2 (ja) | 2016-05-27 | 2022-02-18 | 抗ｃｄ４０抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023569A Active JP7331179B2 (ja) | 2016-05-27 | 2022-02-18 | 抗ｃｄ４０抗体とその使用 |
Country Status (35)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047164T2 (hu) * | 2007-11-01 | 2020-04-28 | Univ Arkansas | Kompozíciók és eljárások eimeria elleni immunválasz fokozására |
| PT3464361T (pt) * | 2016-05-27 | 2021-12-27 | Abbvie Biotherapeutics Inc | Anticorpos anti-cd40 e suas utilizações |
| EP3781203A4 (en) * | 2018-04-20 | 2022-04-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| AU2019383548A1 (en) | 2018-11-23 | 2021-06-24 | Strike Pharma Ab | Bi-specific conjugates |
| KR20210099027A (ko) * | 2018-11-30 | 2021-08-11 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도 |
| US10570210B1 (en) * | 2019-03-04 | 2020-02-25 | Beijing Mabworks Biotech Co.Ltd | Antibodies binding CD40 and uses thereof |
| CN109912717B (zh) * | 2019-03-04 | 2020-05-26 | 北京天广实生物技术股份有限公司 | 结合cd40的抗体及其用途 |
| JP7640466B2 (ja) | 2019-03-27 | 2025-03-05 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | Ｃｄ４０活性化特性を有する組換えタンパク質 |
| AU2020256828A1 (en) | 2019-04-10 | 2021-11-18 | Nankai University | Anti-CD40 antibody and use thereof |
| GB201910900D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
| WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CA3148890A1 (en) * | 2019-09-11 | 2021-03-18 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| CA3158527A1 (en) * | 2019-10-23 | 2021-04-29 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
| EP4056592A4 (en) * | 2019-11-08 | 2024-03-20 | Jiangsu Simcere Pharmaceutical Co., Ltd. | ANTIBODY AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND USE THEREOF |
| IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| GB202008003D0 (en) * | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| WO2022020109A1 (en) * | 2020-07-23 | 2022-01-27 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| CN115403670A (zh) * | 2021-05-26 | 2022-11-29 | 安徽瀚海博兴生物技术有限公司 | 抗cd40抗体及其用途 |
| WO2023232036A1 (zh) * | 2022-05-31 | 2023-12-07 | 明济生物制药（北京）有限公司 | 抗cd40抗体和抗pd-l1×cd40双特异抗体及其应用 |
| CN120035611A (zh) * | 2022-09-20 | 2025-05-23 | 科锐生物制品私人有限公司 | 双特异性多肽及其用途 |
| AR131856A1 (es) * | 2023-02-16 | 2025-05-07 | Sanofi Sa | Proteínas de unión a cd40 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US7172759B2 (en) | 2000-02-01 | 2007-02-06 | Pangenetics Bv | Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP4242388B2 (ja) * | 2003-12-25 | 2009-03-25 | 協和発酵キリン株式会社 | 抗ｃｄ４０抗体の変異体 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2005271892A1 (en) * | 2004-07-10 | 2006-02-16 | Alexion Pharmaceuticals, Inc. | Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US20090074711A1 (en) | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| CA2662340C (en) * | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| NZ585110A (en) * | 2007-10-05 | 2012-09-28 | Genentech Inc | Method and compositions for diagnosis and treatment of amyloidosis |
| SI3178851T1 (sl) * | 2010-03-31 | 2020-09-30 | Boehringer Inhelheim International Gmbh | Anti-CD40 protitelesa |
| SG194701A1 (en) | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| SG10201709559PA (en) * | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| KR102270618B1 (ko) * | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| CA2904528C (en) * | 2013-03-15 | 2021-01-19 | Abbvie Biotherapeutics Inc. | Fc variants |
| GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
| JP6691113B2 (ja) | 2014-10-29 | 2020-04-28 | シアトル ジェネティックス， インコーポレイテッド | 非フコシル化抗ｃｄ４０抗体の投与量および投与 |
| CN107810198B (zh) * | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| PT3464361T (pt) * | 2016-05-27 | 2021-12-27 | Abbvie Biotherapeutics Inc | Anticorpos anti-cd40 e suas utilizações |
| AU2017271601A1 (en) * | 2016-05-27 | 2018-12-13 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
-
2017
- 2017-05-26 PT PT177284114T patent/PT3464361T/pt unknown
- 2017-05-26 KR KR1020227005372A patent/KR20220028143A/ko not_active Withdrawn
- 2017-05-26 CR CR20180605A patent/CR20180605A/es unknown
- 2017-05-26 HU HUE17728411A patent/HUE056670T2/hu unknown
- 2017-05-26 LT LTEPPCT/US2017/034681T patent/LT3464361T/lt unknown
- 2017-05-26 US US15/606,227 patent/US10519243B2/en active Active
- 2017-05-26 WO PCT/US2017/034681 patent/WO2017205742A1/en not_active Ceased
- 2017-05-26 PL PL17728411T patent/PL3464361T3/pl unknown
- 2017-05-26 RU RU2018146533A patent/RU2752049C2/ru active
- 2017-05-26 KR KR1020187037322A patent/KR102366355B1/ko not_active Expired - Fee Related
- 2017-05-26 CA CA3025347A patent/CA3025347A1/en active Pending
- 2017-05-26 AU AU2017271602A patent/AU2017271602A1/en not_active Abandoned
- 2017-05-26 TW TW111109284A patent/TWI814279B/zh not_active IP Right Cessation
- 2017-05-26 BR BR112018074468-9A patent/BR112018074468A2/pt not_active IP Right Cessation
- 2017-05-26 AR ARP170101447A patent/AR108611A1/es not_active Application Discontinuation
- 2017-05-26 TW TW106117521A patent/TWI761348B/zh not_active IP Right Cessation
- 2017-05-26 EP EP17728411.4A patent/EP3464361B1/en active Active
- 2017-05-26 NZ NZ748644A patent/NZ748644A/en not_active IP Right Cessation
- 2017-05-26 PE PE2018003115A patent/PE20190970A1/es unknown
- 2017-05-26 SG SG11201810522UA patent/SG11201810522UA/en unknown
- 2017-05-26 ES ES17728411T patent/ES2901722T3/es active Active
- 2017-05-26 EP EP21200482.4A patent/EP3995511A1/en not_active Withdrawn
- 2017-05-26 SG SG10201914132RA patent/SG10201914132RA/en unknown
- 2017-05-26 MY MYPI2018002113A patent/MY195442A/en unknown
- 2017-05-26 IL IL263223A patent/IL263223B2/en unknown
- 2017-05-26 SM SM20210721T patent/SMT202100721T1/it unknown
- 2017-05-26 SI SI201731001T patent/SI3464361T1/sl unknown
- 2017-05-26 JP JP2018561225A patent/JP2019523221A/ja not_active Withdrawn
- 2017-05-26 MX MX2018014630A patent/MX393455B/es unknown
- 2017-05-26 HR HRP20211882TT patent/HRP20211882T1/hr unknown
- 2017-05-26 UA UAA201812784A patent/UA123111C2/uk unknown
- 2017-05-26 RS RS20211552A patent/RS62726B1/sr unknown
- 2017-05-26 CN CN201780046023.8A patent/CN109476750B/zh active Active
-
2018
- 2018-02-21 US US15/901,560 patent/US10023645B1/en active Active
- 2018-07-16 US US16/036,691 patent/US10400041B2/en active Active
- 2018-11-22 PH PH12018502456A patent/PH12018502456A1/en unknown
- 2018-11-26 CL CL2018003366A patent/CL2018003366A1/es unknown
- 2018-11-26 DO DO2018000258A patent/DOP2018000258A/es unknown
- 2018-11-26 CO CONC2018/0012699A patent/CO2018012699A2/es unknown
- 2018-12-21 EC ECSENADI201894829A patent/ECSP18094829A/es unknown
-
2019
- 2019-09-03 US US16/559,504 patent/US10844131B2/en active Active
- 2019-10-21 US US16/659,209 patent/US10597460B2/en active Active
-
2020
- 2020-10-16 US US17/073,150 patent/US20210024642A1/en not_active Abandoned
-
2021
- 2021-05-21 US US17/327,264 patent/US20210277137A1/en not_active Abandoned
- 2021-12-03 CY CY20211101058T patent/CY1124806T1/el unknown
- 2021-12-30 US US17/566,149 patent/US20220119542A1/en not_active Abandoned
-
2022
- 2022-01-24 AR ARP220100135A patent/AR124692A2/es not_active Application Discontinuation
- 2022-02-18 JP JP2022023569A patent/JP7331179B2/ja active Active